CORRECTING and REPLACING ARYx to Present at the Jefferies 2nd Annual Healthcare Conference

FREMONT, Calif.--(Business Wire)--
First graph, second sentence, time should read 10:15 a.m. Eastern
Time (sted 10:45 a.m. Eastern Time); and second graph, fourth sentence
should read Phase 1 clinical trials (sted preclinical development).

The corrected release reads:

ARYX TO PRESENT AT THE JEFFERIES 2ND ANNUAL HEALTHCARE CONFERENCE

ARYx Therapeutics, Inc. (NASDAQ:ARYX) today announced that it will
present at the Jefferies 2nd Annual Healthcare Conference in New York
City. A live webcast of the presentation scheduled for Wednesday, June
25th at 10:15 a.m. Eastern Time may be accessed at the ARYx website
http://www.aryx.com. The presentation will be archived for seven days.

About ARYx Therapeutics

ARYx Therapeutics is a biopharmaceutical company focused on
developing a portfolio of internally discovered products designed to
eliminate known safety issues associated with well-established,
commercially successful drugs. ARYx uses its RetroMetabolic Drug
Design(TM) technology to design structurally unique molecules that
retain the efficacy of these original drugs but are metabolized
through a potentially safer pathway to avoid specific adverse side
effects associated with these compounds. ARYx currently has three
products in Phase 2 clinical trials: a prokinetic agent for the
treatment of various gastrointestinal disorders, ATI-7505; an oral
anticoagulant agent for patients at risk for the formation of
dangerous blood clots, ATI-5923; and, an oral anti-arrhythmic agent
for the treatment of atrial fibrillation, ATI-2042. A fourth product
for the treatment of schizophrenia and other psychiatric disorders,
ATI-9242, is in Phase 1 clinical trials. Please visit our web site at
www.aryx.com for additional information.

Forward-Looking Statement

This press release contains forward-looking statements, including,
without limitation, statements related to the timing and availability
of clinical results, the initiation of new clinical trials, the
completion of preclinical work, the ability of preclinical packages to
lead to further clinical trials, the ability of the Company to enter
into collaboration agreements, the ability of a product candidate to
be more predictable than currently available therapies regarding
dosing and response to treatment, and the ability of a product
candidate to avoid the dangers existing in currently available
therapies. Words such as "expected," "potentially," "believe," "will
be used," "continues," and similar expressions are intended to
identify forward-looking statements. These forward-looking statements
are based upon the company's current expectations. Forward-looking
statements involve risks and uncertainties. The company's actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of these
risks and uncertainties, which include, without limitation, the risk
that collaborative arrangements will likely place the development of
our product candidates outside of our control, the risk that we may
have to alter our development and commercialization plans if
collaborative relationships are not established for ATI-5923 and
ATI-2042, the risk that the company may be unable to raise additional
capital when needed which would force the company to delay, reduce or
eliminate product development programs, the risk that any failure or
delay in commencing or completing clinical trials for the company's
product candidates could severely harm our business, and the risk that
third party manufacturers could delay or prevent the clinical
development of our product candidates. These and other risk factors
are discussed under "Risk Factors" and elsewhere in the company's
Annual Report on Form 10-K for the year ended December 31, 2007. The
company expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein.

ARYx Therapeutics, Inc.
David Nagler, 510-585-2200 ext. 211
Vice President, Corporate Affairs

Copyright Business Wire 2008